Tuesday, July 21, 2026

CMS finalized its framework requiring all off-campus provider-based departments (PBDs) to submit a mandatory attestation and obtain a separate National Provider Identifier (NPI). The rule, included in the 2027 Hospital Outpatient Prospective Payment System, aims to enforce site-neutral payment policies and clarify billing location status. Facilities must attest to their off-campus status and report specific service-line information. Failure to comply will affect Medicare reimbursement for services furnished at non-compliant locations. Practices billing under hospital outpatient department arrangements should immediately verify their PBD's attestation status and prepare to submit required data by the CMS deadline, which is expected before the 2027 calendar year.

A Democratic attempt to end CMS's Medicare AI prior authorization pilot program failed in the Senate after Republican opposition. The pilot, which uses algorithms to automate review for certain services, will continue despite provider concerns about increased denials and lack of transparency. This outcome indicates sustained federal support for automating administrative processes within Medicare, aligning with broader efforts to reduce manual review burdens. Billing teams should monitor denial patterns for services included in the pilot, such as select radiology and durable medical equipment codes, and prepare appeals that challenge algorithmic decisions with specific clinical documentation.

The 2027 Hospital Outpatient Prospective Payment System proposed rule includes further steps toward site-neutral payments, continuing a multi-year effort to equalize reimbursement for identical services regardless of setting. The rule targets additional clinical families of services where payment differentials between hospital outpatient departments and independent physician offices remain significant. If finalized, this will accelerate the revenue compression for hospital-owned clinics and increase competitive pressure on independent practices to demonstrate value beyond price. Review the proposed rule's service list when published to model the financial impact on your practice's procedural mix, especially for evaluation and management, imaging, and minor procedures.

Lawmakers are pressing to advance bipartisan hospital price transparency legislation before Congress leaves for the August recess. The push targets hospitals' compliance with existing transparency rules and aims to strengthen enforcement. This follows ongoing frustration from employers and insurers over hidden pricing. The move signals a legislative priority that could force hospitals to publish more granular, machine-readable price data. Monitor the House and Senate calendars for markups in late July.

New research from the University of Mississippi details systemic barriers to insurance coverage for GLP-1 drugs like Ozempic and Wegovy. The study found that payers frequently restrict access through prior authorization, step therapy, and high out-of-pocket costs, pushing patients toward potentially risky compounded versions. The researchers warn that compounded semaglutide may lack safety and efficacy data. This adds academic weight to a widespread clinical access problem. The findings underscore the coverage battles practices face when prescribing these medications.